The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine

NCT05273528 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Pandemic

Interventions

BIOLOGICAL: Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine

Sponsor

Livzon Pharmaceutical Group Inc.